Reversible spastic and pyramidal tract signs in a patient with Parkinson's disease on L-dopa

Case Reports

S Seyfert et al. J Neurol. 1977.

. 1977 Oct 7;216(3):223-6.

doi: 10.1007/BF00313624.

No abstract available

Similar articles

[Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
Boudin G, Pepin B, Guillard A, Godlewski S, Fabiani JM, Haguenau M. Boudin G, et al. Rev Neurol (Paris). 1974 Jul-Aug;130(7-8):273-84. Rev Neurol (Paris). 1974. PMID: 4217929 French. No abstract available.
[Long-term levodopa syndrome. Report of a clinical case].
Bossi L, Nobili M. Bossi L, et al. Arch Sci Med (Torino). 1978 Oct-Dec;135(4):637-9. Arch Sci Med (Torino). 1978. PMID: 756726 Italian.
[The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
Sommer H, Fischer GJ, Quandt J. Sommer H, et al. Folia Clin Int (Barc). 1974 Oct;24(10):681-95. Folia Clin Int (Barc). 1974. PMID: 4279185 Spanish. No abstract available.
[Pallido-pyramidal syndrome: an unrecognized entity].
Tranchant C, Boulay C, Warter JM. Tranchant C, et al. Rev Neurol (Paris). 1991;147(4):308-10. Rev Neurol (Paris). 1991. PMID: 2063080 Review. French.
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Zigmond MJ, Hastings TG, Abercrombie ED. Zigmond MJ, et al. Ann N Y Acad Sci. 1992 May 11;648:71-86. doi: 10.1111/j.1749-6632.1992.tb24525.x. Ann N Y Acad Sci. 1992. PMID: 1637074 Review. No abstract available.